利奈唑胺的PK/PD与给药方案优化设计研究进展

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (12): 1429-1434.

利奈唑胺的PK/PD与给药方案优化设计研究进展

金砚杰^1,2, 张晶¹, 卢克鹏^1,3, 刘倩^1,3, 林立敏^1,3, 宋洪涛^1,2,3

¹南京军区福州总医院药学科,福州 350025,福建;
²福建医科大学药学院,福州 350108,福建;
³沈阳药科大学药学院,沈阳 110016,辽宁

收稿日期:2013-12-27 修回日期:2014-06-23 发布日期:2020-07-20
通讯作者: 宋洪涛,通信作者,男,主任药师,博士生导师,研究方向:药物基因组学与个体化给药。Tel:0591-22859459 E-mail:sohoto@vip.163.com
作者简介:金砚杰,男,硕士研究生,研究方向:临床药学。Tel:15705960897 E-mail:150300298@qq.com

Linezolid pharmacokinetics/pharmacodynamics and the development of dosage regimen design optimization

JIN Yan-jie^1,2, ZHANG Jing¹, LU Ke-peng^1,3, LIU Qian^1,3, LIN Li-min^1,3, SONG Hong-tao^1,2,3

¹Fuzhou General Hospital of Nanjing Command, PLA, Fuzhou 350025, Fujian, China;
²Fujian Medical University, Fuzhou 350108, Fujian, China;
³Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China

Received:2013-12-27 Revised:2014-06-23 Published:2020-07-20

摘要/Abstract

摘要： 通过CNKI、PUBMED等文献库查阅相关文献进行分析,介绍利奈唑胺在不同疾病中PK/PD特点,从而为临床合理应用提供参考。以PK/PD参数为依据,对给药方案进行优化,可以更好地发挥抗菌药物的临床治疗效果,降低不良反应和耐药性的发生率,减轻患者经济负担。利奈唑胺具有强大的抗革兰阳性菌活性,由于不同病理生理因素与其PK/PD特点,研究优化给药方案、促进合理用药具有重大意义。

关键词: 利奈唑胺, PK/PD, 疾病, 给药方案

Abstract: To provide reference for clinical reasonable application by introducing linezolid pharmacokinetics and pharmacodynamics characteristics in different diseases. The data from CNKI,PUBMED were analyzed. On the basis of PK/PD parameters, the dosage regimen was optimized, which could better improve the curative effect of antimicrobial drugs, and reduce the incidence of adverse reactions, drug resistance and the patients' economic burden. Linezolid had strong antibacterial effect against gram-positive bacteria. It is meaningful to study on the optimum dosage regimen and promote the rational drug use due to the different pathological physiological factors instead of PK/PD characteristics.

Key words: linezolid, PK/PD, disease, dosage regimen

中图分类号:

R969.1

金砚杰, 张晶, 卢克鹏, 刘倩, 林立敏, 宋洪涛. 利奈唑胺的PK/PD与给药方案优化设计研究进展[J]. 中国临床药理学与治疗学, 2014, 19(12): 1429-1434.

JIN Yan-jie, ZHANG Jing, LU Ke-peng, LIU Qian, LIN Li-min, SONG Hong-tao. Linezolid pharmacokinetics/pharmacodynamics and the development of dosage regimen design optimization[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1429-1434.

参考文献

[1] Leach KL, Brickner SJ, Noe MC. Linezolid the first oxazolidinone antibacterial agent[J]. Ann N Y Acad Sci, 2011,1222: 49-54.
[2] Diekema DJ,Jones RN.Oxazolidinones[J].Drugs,2000,59(1):7-16.
[3] Meyer B,Kornek GV,Nikfardjam M,et al.Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration[J].Antimicrob Chemother,2005,56(1):172-179.
[4] Beer R,Engelhardt KW,Pfausler B,et al.Phar-macokinetics of intravenous linezolid in cerebrospinal fluid andplasma in neurointensive care patients with Staphylococcal ventriculitis associated with external ventricular drains[J].Antimicrob Agents Chemother,2007,51(1):379-382.
[5] Kearns GL, Abdel-Rahman SM, Blumer JL, et al. Single dose pharmacokinetics of linezolid in infants and children[J]. Pediatr Infect Dis J, 2011, 19(12): 1178-1184.
[6] Zhao C,Sun H,Wang H. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China:results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010)[J]. Diagn Microbiol Infect Dis, 73(2):174-181.
[7] Vardakas KZ,kioumis I,Falagas ME.Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome[J].Curr Drug Metab,2009,10(1):2-12.
[8] Rayner CR,Forrest A,Meagher AK,et al.Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme[J].Clin Pharmacokinet,2003,42(15):1411-1423.
[9] Slatter JG,Stalker DJ,Feenstra KL,et al.Pharmacokinetics,metabolism,and excretion of linezolid following an oral dose of linezolid to healthy human subjects[J].Drug Metab Dispos,2001,29(8):1136-1145.
[10] 陈玉麟,李谦,张文宏.利奈唑胺致5-羟色胺综合征一例[J].中华传染病杂志,2013, 31(11):701-702.
[11] Gee T,Ellis R,Marshall G,et al.Pharmacokinetics and tissue penetration of linezolid following multiple oral doses[J].Antimicrob Agents Chemother, 2001,45:1843-1845.
[12] Traunmuller F,Schintler MV,Spende S,et al.Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections[J].Antimicrob Agents,2010,36(1):84-86.
[13] Stein GE,Schooley S,Peloquin CA,et al.Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections[J]. Antimicrob Chemother,2007,60(4):819-823.
[14] Lovering AM, Zhang J, Bannister GC,et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement[J]. Antimicrob Chemother,2002,50(1):73-77.
[15] Kutscha-Lissberg F, Hebler U, Muhr G,et al. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci[J].Antimicrob Agents Chemother,2003,47(12):3964-3966.
[16] Legout L,Valette M,Dezeque H,et al.Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia[J].Antimicrob Chemother,2010,65(10):2224-2230.
[17] Conte JE Jr,Golden JA,Kipps J,et al.Intrapulmonary pharmacokinetics of linezolid[J].Antimicrob Agents Chemother,2002,46(5):1475-1480.
[18] Boselli E,Breilh D,Rimmele T,et al.Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia[J].Crit Care Med,2005,33(7):1529-1533.
[19] Birmingham MC,Rayner CR,Meagher AK,et al.Linezolid for the treatment of multidrug-resistant,Grampositive infections experience from a compassionate use program[J].Clin Infect Dis,2003,36(15):159-168.
[20] Velez JC,JanechMG,Medscape.A case of lactic acidosis induced by linezolid[J]. NatRev Nephrol,2010,6(4):236-242.
[21] Serisier DJ,Jones G,Carroll M.Eradication of pulmonary methicillin-resistant Staphylococcus aureus(MRSA)in cystic fibrosis with linezolid[J].J Cyst Fibros,2004,3(1):61.
[22] Rayner CR,Forrest A,Meagher AK,et al.Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme[J].Clin Pharmacokinet,2003,42(15):1411-1423.
[23] Brier ME,Stalker DJ,Aronoff GR,et al. Pharmacokinetics of linezolid in subjects with renal dysfunction[J].Antimicrob Agents Chemother,2003,47(9):2775-2780.
[24] Fiaccadori E,Maggiore U,Rotelli C,et al.Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure A pilot investigation[J].Nephrol Dial Transplant,2006,21(5):1402-1406.